– USA, CA – Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced the appointment of Cristina Larkin, Dr. Bruce Montgomery (MD), and Dr. Michael Lamprecht (Ph.D.) to its Board of Directors in conjunction with closing its Series B funding round.
As part of this transition, Andrew Calabrese and Aleks Engel will step down from the Board.
About Revagenix
Revagenix is dedicated to creating life-changing antibiotics, providing urgently needed anti-infective medicines to patients globally. We are advancing a focused pipeline designed to treat infections caused by multidrug-resistant organisms. The team—composed of seasoned industry experts, and augmented by a world-class network of strategic collaborators, partners, investors, and advisors—leverages extensive experience in anti-infective research, development, and commercialization. Together, we are developing the next generation of antibiotics to address the critical need for new treatments in the face of increasing antibiotic resistance.
For more information https://www.revagenix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
